A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis

Inclusion Criteria:

• Men or women, aged 18-65 years old
• Prior endoscopic confirmation of UC:

Mildly to moderately active UC with Simple Clinical Colitis Activity Index (SCCAI) activity index >4-9

• Failing standard therapy with:

stable doses of 5-ASA >2 weeks; thiopurines >3 months; or is steroid dependent at a dose <20mg/d; (inability to taper off steroid for longer than 1 week)

• Stable medications dose for at least 2 weeks prior to screening and upon entry into trial
• Ability to understand and willingness to sign informed consent document

Exclusion Criteria:

• Diagnosis of Crohn's disease, indeterminate colitis, or proctitis alone
• Severe or fulminate colitis
• Women who are pregnant or nursing
• Patients who are unable to give informed consent
• Patients who are unable or unwilling to undergo colonoscopy
• Patients who have previously undergone FMT
• Patients who have a confirmed malignancy or cancer
• Patients who are immunocompromised
• Treatment within last 12 weeks with cyclosporine, tacrolimus, infliximab, adalimumab, certolizumab, natalizumab, thalidomide
• Antibiotic use within 2-months of start date
• Participation in a clinical trial in the preceding 30 days or simultaneously during this trial
• Probiotic use within 30 days of start date
• Rectal therapy within 14 days of start date
• Decompensated cirrhosis
• Congenital or acquired immunodeficiencies
• Other comorbidities including:

Diabetes mellitus, cancer, systemic lupus, must be able to tolerate conscious sedation with colonoscopy

• Chronic kidney disease as defined by a GFR <60mL/min/1.73m2 (40)
• History of rheumatic heart disease, endocarditis, or valvular disease due to risk of bacteremia.
• Steroid >20mg/day
• Positive screening and confirmatory tests for HIV 1 & 2, Hepatitis A, B, & C, and Syphilis